Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC)

C.C. Lin (C. Christine), Joerger, M, Grell, P., Chiappori, A.A., Leal, T.A., Kasper, S., Jerusalem, G., Gonçalves, A., van der Wolf, J., F. de Braud (Filippo), et al. Otero, J., Morris, E, Tan, D.S.W.

2020-10-01

European Journal of Cancer , Volume 138 p. S12- S13

Additional Metadata
Persistent URL	doi.org/10.1016/s0959-8049(20)31098-4, hdl.handle.net/1765/133853
Journal	European Journal of Cancer
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Lin, C. C., Joerger, M, Grell, P., Chiappori, A.A., Leal, T.A., Kasper, S., … Tan, D.S.W. (2020). Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC). European Journal of Cancer, 138, S12–S13. doi:10.1016/s0959-8049(20)31098-4

Publication